Research programme: 8-oxoguanine DNA glycosylase agonists - Luciole Pharmaceuticals/Cyclica
Latest Information Update: 27 Jan 2022
At a glance
- Originator Luciole Pharmaceuticals
- Class Neuroprotectants; Small molecules
- Mechanism of Action Oxoguanine glycosylase 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Neurodegenerative disorders
Most Recent Events
- 24 Jan 2022 Luciole Pharmaceuticals and Oregon Health & Science University (OHSU) enters into aresearch agreement to accelerate the discovery of small molecule agonists of OGG1
- 13 Oct 2021 Luciole Pharmaceuticals and Cyclica collaborate to develop OGG1 agonists for the treatment of Neurodegenerative disorders
- 13 Oct 2021 Early research in Neurodegenerative disorders in USA (unspecified route)